论文部分内容阅读
采用微量培养板的细胞病变抑制法,检测各种癌症病人血液中α—干扰素抑制物。共检测43份标本,其中含有干扰素抑制物的有28份,占65.12％;正常对照血清77份,仅26份阳性,占33.78％(T=2.31,P<0.05)二者有显著差别。鼻咽癌、宫颈癌、肠癌、肺癌病人血清的阳性率,分别为53.85％、62.50％、71.43％、85.71％。患者是否经过放疗与发病年龄对血清中干扰素抑制物的阳性率并无影响。结果提示,癌症患者体液内无干扰素抑制物,可能是患者接受干扰素治疗的前提。
Microbial platelet cytopathic inhibition assay was used to detect alpha-interferon inhibitors in the blood of various cancer patients. A total of 43 specimens were detected, 28 of them contained interferon inhibitors, accounting for 65.12%; 77 of normal control serum, only 26 were positive and accounted for 33.78% (T=2.31, P<0.05). The positive rates of serum from patients with nasopharyngeal carcinoma, cervical cancer, colon cancer, and lung cancer were 53.85%, 62.50%, 71.43%, and 85.71%, respectively. Whether or not the patient had undergone radiotherapy and age of onset had no effect on the positive rate of interferon-inhibitor in serum. The results suggest that there are no interferon inhibitors in the body fluids of cancer patients and may be a prerequisite for patients receiving interferon therapy.